Expert Opinion on Investigational Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Current experimental and early investigational agents for cardiac fibrosis: where are we at?
This article is aimed to describe anti-fibrotic drugs currently employed in clinical practice and emerging agents that target specific pathways, supported by evidence from both preclinical and clinical studies.EXPERT OPINION: despite various preclinical findings suggesting the potential utility of new drugs and molecules for treating cardiac fibrosis in animal models, there is a notable scarcity of clinical trials investigating these effects. However, the pathology of damage and repair in the heart muscle involves a complex network of interconnected inflammatory pathways and various types of immune cells. Our comprehension...
Source: Expert Opinion on Investigational Drugs - March 1, 2024 Category: Drugs & Pharmacology Authors: Claudio M Ciampi Andrea Sultana Paolo Ossola Andrea Farina Gabriele Fragasso Roberto Spoladore Source Type: research

Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes
Expert Opin Investig Drugs. 2024 Mar 1. doi: 10.1080/13543784.2024.2326036. Online ahead of print.ABSTRACTINTRODUCTION: . Despite the improvements of insulin therapy, people with type 1 diabetes (T1D) still suffer from a decreased quality of life and life expectancy. The search toward a cure for T1D is therefore still a scorching open field of research.AREAS COVERED: Tackling the immune checkpoint signaling pathways has gained importance in the field of cancer immunotherapy. The same pathways can be targeted in autoimmunity with an opposite principle: to dampen the exaggerated immune response. In this review, we report a c...
Source: Expert Opinion on Investigational Drugs - March 1, 2024 Category: Drugs & Pharmacology Authors: Ernesto Maddaloni Rocco Amendolara Angela Balena Alessandro Latino Rosario Luigi Sessa Raffaella Buzzetti Source Type: research

Early investigational agents for the treatment of benign prostatic hyperplasia'
Expert Opin Investig Drugs. 2024 Feb 29. doi: 10.1080/13543784.2024.2326023. Online ahead of print.ABSTRACTINTRODUCTION: Benign prostatic hyperplasia (BPH), as a clinical entity that affects many people, has always been in the forefront of interest among researchers, pharmaceutical companies, and physicians. Patients with BPH exhibit a diverse range of symptoms, while current treatment options can occasionally cause adverse events. All the aforementioned have led to an increased demand for more effective treatment options.AREAS COVERED: This review summarizes the outcomes of new medications used in a pre-clinical and clini...
Source: Expert Opinion on Investigational Drugs - February 29, 2024 Category: Drugs & Pharmacology Authors: Stamatios Katsimperis Konstantinos Kapriniotis Ioannis Manolitsis Themistoklis Bellos Panagiotis Angelopoulos Patrick Julieb ø-Jones Bhaskar Somani Andreas Skolarikos Lazaros Tzelves Source Type: research

A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis
Expert Opin Investig Drugs. 2024 Feb 26:1-7. doi: 10.1080/13543784.2024.2323528. Online ahead of print.ABSTRACTINTRODUCTION: The potent profibrotic cytokine transforming growth factor-β (TGF-β) has been associated with the onset and progression of the fibrosis seen in the autoimmune connective tissue disease scleroderma (systemic sclerosis, SSc).AREA COVERED: This review explores the data supporting the notion that TGF-β contributes to SSc fibrosis and examines why initiating clinical trials in SSc aimed at targeting integrin-mediated latent TGF-β activation is timely.EXPERT OPINION: Targeting TGF-β directly has not b...
Source: Expert Opinion on Investigational Drugs - February 23, 2024 Category: Drugs & Pharmacology Authors: Andrew Leask Asmaa Fadl Angha Naik Source Type: research

A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis
Expert Opin Investig Drugs. 2024 Feb 23. doi: 10.1080/13543784.2024.2323528. Online ahead of print.ABSTRACTINTRODUCTION: The potent profibrotic cytokine transforming growth factor-β (TGF-β) has been associated with the onset and progression of the fibrosis seen in the autoimmune connective tissue disease scleroderma (systemic sclerosis, SSc).AREA COVERED: This review explores the data supporting the notion that TGF-β contributes to SSc fibrosis and examines why initiating clinical trials in SSc aimed at targeting integrin-mediated latent TGF-β activation is timely.EXPERT OPINION: Targeting TGF-β directly has not been ...
Source: Expert Opinion on Investigational Drugs - February 23, 2024 Category: Drugs & Pharmacology Authors: Andrew Leask Asmaa Fadl Angha Naik Source Type: research

The impact of current investigational drugs for acne on future treatment strategies
Expert Opin Investig Drugs. 2024 Feb;33(2):127-132. doi: 10.1080/13543784.2024.2313091. Epub 2024 Feb 19.ABSTRACTINTRODUCTION: Acne vulgaris is one of the most prevalent diseases worldwide with a considerably high cost and a burden on quality of life. There are currently many topical and systemic therapies for acne; however, many are limited by their local adverse event profile. This review provides an update on current, novel Phase I and II trials for acne vulgaris.AREAS COVERED: This review searched the National Institutes of Health US National Library of Medicine online database of clinical trials (ClinicalTrials.gov) f...
Source: Expert Opinion on Investigational Drugs - February 19, 2024 Category: Drugs & Pharmacology Authors: Heli A Patel Lily Guo Steven R Feldman Source Type: research

GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates
This article reviews studies focused on GPR119 agonism in animal models of T2D and in patients with T2D.EXPERT OPINION: GPR119 agonists in vitro and in vivo can potentially regulate incretin hormone release from the gut, then pancreatic insulin release which regulates blood glucose concentrations. However, the success in controlling glucose homeostasis in rodent models of T2D and obesity, failed to translate to early-stage clinical trials in patients with T2D. However, in more recent studies, acute and chronic dosing with the GPR119 agonist DS-8500a had increased efficacy, although this compound was discontinued for furthe...
Source: Expert Opinion on Investigational Drugs - February 19, 2024 Category: Drugs & Pharmacology Authors: Deanne H Hryciw Rhiannon K Patten Raymond J Rodgers Joseph Proietto Dana S Hutchinson Andrew J McAinch Source Type: research

Correction
Expert Opin Investig Drugs. 2024 Feb;33(2):159. doi: 10.1080/13543784.2024.2319956. Epub 2024 Feb 19.NO ABSTRACTPMID:38372200 | DOI:10.1080/13543784.2024.2319956 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - February 19, 2024 Category: Drugs & Pharmacology Source Type: research

Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions
Expert Opin Investig Drugs. 2024 Feb 23:1-12. doi: 10.1080/13543784.2024.2320710. Online ahead of print.ABSTRACTINTRODUCTION: Targeted therapy is used to treat lung adenocarcinoma caused by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain and rare subtypes (<5%) of non-small cell lung cancer. These subtypes include fusion oncoproteins like anaplastic lymphoma kinase (ALK), ROS1, rearranged during transfection (RET), and other receptor tyrosine kinases (RTKs). The use of diverse selective oral inhibitors, including those targeting rat sarcoma viral oncogene homolog (KRAS) mutations, has sig...
Source: Expert Opinion on Investigational Drugs - February 19, 2024 Category: Drugs & Pharmacology Authors: Rafael Rosell Carlos Pedraz-Valdunciel Anisha Jain Chandan Shivamallu Andr és Aguilar Source Type: research